According to a new study, rapamycin probably interferes with exercise, blunting its effects in older human subjects. This result, however, might be specific to the particular protocol.
Can they work together?
Physical activity is one of the most potent pro-longevity interventions currently available [2]. Rapamycin is the undisputed champion of small molecules for extending lifespan in animal models, although human data is scarce. It would seem sensible to combine those two for a synergistic effect, but they are in an intrinsic tug-of-war with each other.
Rapamycin blocks mTORC1, an important regulator of nutrient sensing, switching the organism from the “building mode” to the “maintenance mode.” Growth (anabolism) is attenuated, while intracellular cleanup (autophagy) is upregulated, which results in robust longevity gains in model organisms. Exercise, on the other hand, builds muscle mass and endurance by increasing anabolic activity. This conflict has unclear outcomes for humans in real life.
The “cycling hypothesis” suggests that spacing out rapamycin administration might help mitigate the tension with exercise, giving us the best of the two worlds. To test it, an international group of researchers, supported by Lifespan Research Institute as a fiscal sponsor, conducted a trial, the results of which have been published in the Journal of Cachexia, Sarcopenia and Muscle.
“Lifespan Research Institute has been a wonderful partner that enabled this trial to be done. I’m incredibly thankful for their support,” said Brad Stanfield, one of the authors, to Lifespan News. “Going in, we hoped the ‘cycling hypothesis’ would alleviate anabolic resistance (meaning that older adults would see improved muscle performance when rapamycin was combined with exercise, compared to just exercise alone).”
Rapamycin seems to make things worse
The team recruited 40 sedentary adults aged 65-85 who were treated once a week with 6 mg of rapamycin (sirolimus) or placebo, alongside a 13-week home exercise program, with dosing timed to the rest day furthest from the next workout. The question of the randomized, double-blind, and placebo-controlled trial was simple: does weekly rapamycin help, hurt, or have no effect on the functional gains people get from exercise?
“We hoped that weekly rapamycin dosed 24 hours after the last workout would preserve the autophagy benefits of mTORC1 inhibition while leaving room for post-exercise adaptation. It didn’t,” said Stanfield. “One explanation is that rapamycin’s about 62-hour half-life likely kept mTORC1 partially inhibited into the next training week.”
Both groups did the same home exercise program three times a week: a resistance component of 30-second chair-stands, progressed by asking participants to do more reps in the fixed 30-second window, and an endurance component on a magnetic-resistance stationary bike that ramped from 10 minutes at Level 1 to 25 minutes at Level 5 over the 13 weeks. The authors did not measure pharmacodynamic markers to confirm that mTORC1 was actually being inhibited as expected, instead relying on prior literature showing that 5-6 mg weekly does so for 5-7 days.
Both groups improved their chair-stand performance over 13 weeks. The placebo group improved more, although this primary endpoint did not reach statistical significance. Two prespecified sensitivity analyses sharpened the picture with statistically significant results favoring the placebo group: the complete-case analysis (only participants with both baseline and Week-13 data) and the per-protocol analysis (participants who completed 75% or more of doses and exercise sessions). The other functional measurements, including six-minute walk distance and grip strength, all pointed in the same direction (a win for placebo) but fell short of reaching statistical significance.
Consistency matters here: across several independent outcomes, the rapamycin arm underperformed, which is exactly what you’d expect if the drug is genuinely blunting adaptation to exercise. The study was powered to detect only large effects, so smaller-but-real effects would be expected to miss significance.
The team also measured exploratory mechanistic outcomes, including epigenetic clocks and C-reactive protein (CRP), a blood marker of systemic inflammation. Surprisingly, rapamycin participants had higher inflammation on average, although this was driven by two outliers with unusually high CRP levels; excluding them reduced the difference to less than 1 mg/L. So, at the very least, rapamycin did not meaningfully reduce inflammation, contrary to a common hypothesized benefit of the drug.
Four epigenetic age measurements, PCGrimAge, SystemsAge, OMICmAge, and DunedinPACE, showed mixed, non-significant trends. PCGrimAge trended toward a younger biological age in the rapamycin arm, but the other three clocks showed no pattern or slightly favored placebo. Several lab parameters also shifted modestly in the rapamycin arm: HbA1c and LDL cholesterol both rose slightly.
17 of 20 participants in each arm reported at least one adverse event, but the total number of events was higher in the rapamycin arm. Events judged to be possibly or probably drug-related were more than twice as common in the rapamycin arm (35% vs. 15%). Only one serious adverse event occurred, and it was in the rapamycin arm: a participant developed community-acquired pneumonia, requiring hospitalization. Because rapamycin is immunosuppressive, a causal contribution cannot be excluded.
It’s still too early to tell
“This is a single dose, schedule, and population study, so it isn’t a verdict on rapamycin generally,” said Stanfield. “But within that window, the signal is internally consistent: the primary outcome pointed against enhancement, every secondary functional outcome directionally favored placebo, and the per-protocol effect size was large. That pattern is hard to dismiss as noise, and it lines up with classic rodent overload studies and acute human muscle-protein-synthesis data showing rapamycin blunts the anabolic response to loading.”
Stanfield maintains that there is “real biological tension” between mTORC1 being the master regulator of muscle protein synthesis and sustained mTORC1 inhibition, which is probably responsible for rapamycin’s geroprotective effect. “Timing (‘cycling’) was the hypothesized workaround, but at weekly 6 mg, the pharmacokinetics don’t cooperate,” he said. “Whether longer interdose intervals or much longer treatment durations can strike the right balance is genuinely open. Until we have answers to these questions, my stance since the beginning remains the same: I recommend against off-label rapamycin use. In the meantime, regular exercise remains the unequivocal first line for preserving function in older adults.”
Another co-author, the renowned geroscientist Matt Kaeberlein, disagreed “with the blanket position that rapamycin should never be prescribed off-label.” In a thorough X post, he said: “While we absolutely need better clinical data, there is already a growing body of evidence – along with clinical experience – suggesting benefit in specific contexts. My hypothesis is that the apparent attenuation in functional gains is likely a short-term effect. If the study had extended to 12 months instead of 13 weeks, I would predict the rapamycin group to show improvement.”
“Given that mTOR activation is required for muscle protein synthesis, it’s not surprising that early hypertrophic responses could be blunted,” he added. “But over longer timeframes – especially with intermittent or cycled dosing – it is entirely plausible (and, in my view, likely) that rapamycin could ultimately enhance functional outcomes in older adults.”
Literature
[1] Stanfield, B., Leroux, B., Kaeberlein, M., Jones, J., & Lucas, R. (2026). Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA‐EX‐01 Randomised, Double‐Blind, Placebo‐Controlled Trial. Journal of Cachexia, Sarcopenia and Muscle, 17(2), e70274.
[2] Ruegsegger, G. N., & Booth, F. W. (2018). Health benefits of exercise. Cold Spring Harbor perspectives in medicine, 8(7), a029694.
[3] Miller, R. A., Harrison, D. E., Astle, C. M., Fernandez, E., Flurkey, K., Han, M., … & Strong, R. (2014). Rapamycin‐mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging cell, 13(3), 468-477.
View the article at lifespan.io
